HRP20041026A2 - Polycyclic compounds as potent alpha2-adrenoceptor antagonists - Google Patents

Polycyclic compounds as potent alpha2-adrenoceptor antagonists

Info

Publication number
HRP20041026A2
HRP20041026A2 HR20041026A HRP20041026A HRP20041026A2 HR P20041026 A2 HRP20041026 A2 HR P20041026A2 HR 20041026 A HR20041026 A HR 20041026A HR P20041026 A HRP20041026 A HR P20041026A HR P20041026 A2 HRP20041026 A2 HR P20041026A2
Authority
HR
Croatia
Prior art keywords
polycyclic compounds
adrenoceptor antagonists
alpha2
potent
potent alpha2
Prior art date
Application number
HR20041026A
Other languages
English (en)
Inventor
Din Belle David
Jokela Reija
Tolvanen Arto
Haapalinna Antti
Karjalainen Arto
Sallinen Jukka
Ratilainen Jari
Original Assignee
Orion Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FI20020642A external-priority patent/FI20020642A0/fi
Application filed by Orion Corporation filed Critical Orion Corporation
Publication of HRP20041026A2 publication Critical patent/HRP20041026A2/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D455/00—Heterocyclic compounds containing quinolizine ring systems, e.g. emetine alkaloids, protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/14—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Psychology (AREA)
  • Reproductive Health (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Gynecology & Obstetrics (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Secondary Cells (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Steroid Compounds (AREA)
  • Peptides Or Proteins (AREA)
HR20041026A 2002-04-03 2003-04-03 Polycyclic compounds as potent alpha2-adrenoceptor antagonists HRP20041026A2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US36934702P 2002-04-03 2002-04-03
FI20020642A FI20020642A0 (fi) 2002-04-03 2002-04-03 Polysykliset yhdisteet tehokkaina alfa2-adrenoseptoriantagonisteina
PCT/FI2003/000255 WO2003082866A1 (en) 2002-04-03 2003-04-03 Polycyclic compounds as potent alpha2-adrenoceptor antagonists

Publications (1)

Publication Number Publication Date
HRP20041026A2 true HRP20041026A2 (en) 2005-06-30

Family

ID=28676457

Family Applications (1)

Application Number Title Priority Date Filing Date
HR20041026A HRP20041026A2 (en) 2002-04-03 2003-04-03 Polycyclic compounds as potent alpha2-adrenoceptor antagonists

Country Status (19)

Country Link
US (1) US7592350B2 (de)
EP (1) EP1490361B1 (de)
JP (1) JP2005522468A (de)
CN (1) CN100372845C (de)
AT (1) ATE374773T1 (de)
AU (1) AU2003216760A1 (de)
BR (1) BR0309028A (de)
CA (1) CA2480695A1 (de)
DE (1) DE60316672T2 (de)
EA (1) EA008537B1 (de)
HR (1) HRP20041026A2 (de)
HU (1) HUP0500201A2 (de)
IL (1) IL164203A0 (de)
IS (1) IS7482A (de)
MX (1) MXPA04009601A (de)
NZ (1) NZ535950A (de)
PL (1) PL372657A1 (de)
RS (1) RS87204A (de)
WO (1) WO2003082866A1 (de)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI457122B (zh) 2007-07-20 2014-10-21 Orion Corp 作為用於治療周邊和中央神經系統疾病之alpha2C拮抗劑的2,3－二氫苯並[1,4]戴奧辛－2－基甲基衍生物
US8906647B2 (en) 2008-02-21 2014-12-09 Sequoia Pharmaceuticals, Inc. Diamide inhibitors of cytochrome P450
TW201024282A (en) 2008-11-20 2010-07-01 Orion Corp New pharmaceutical compounds
WO2011038163A1 (en) 2009-09-23 2011-03-31 Medivation Technologies, Inc. Pyrido[3,4-b]indoles and methods of use
GB2503187A (en) * 2011-09-15 2013-12-25 Univ Sussex Composition for use in the treatment of neurodevelopmental disorders
AR104882A1 (es) 2015-06-05 2017-08-23 Orion Corp DERIVADOS DE 2-(1-HETEROARILPIPERAZIN-4-IL)METIL-1,4-BENZODIOXANO COMO ANTAGONISTAS DE a2C
CN107286158A (zh) * 2016-03-30 2017-10-24 中国科学院上海药物研究所 苯基[a]吲哚[2,3-g]并喹嗪类化合物、其制备方法、药物组合物及其应用
EP3478676A1 (de) 2016-06-29 2019-05-08 Orion Corporation Benzodioxanderivate und deren pharmazeutische verwendung
CN112601527B (zh) 2018-03-31 2024-12-31 分子国际研究公司 用于有效预防和治疗的选择性抗癌剂
CN110922412A (zh) * 2018-09-20 2020-03-27 复旦大学 具有抗精神病作用药物化合物的不对称合成方法
IT201800009072A1 (it) * 2018-10-01 2020-04-01 Universita' Degli Studi Di Cagliari IL COMPOSTO (8aR,12aS,13aS)-5,8,8a,9,10,11,12,12a, 13,13a-DECAIDRO-3-METOSSI-12-(ETILSOLFONIL)-6H-ISOCHINO [2,1-g][1,6]NAFTIRIDINA PER L’USO NEL TRATTAMENTO DELLE PSICOSI
WO2020072675A1 (en) * 2018-10-02 2020-04-09 Northwestern University Beta-carbolines as positive allosteric modulators of the human serotonin receptor 2c (5-ht2c)
EP3965762A1 (de) 2019-05-09 2022-03-16 Bayer Aktiengesellschaft Kombination aus alpha-2-adrenozeptor-subtyp c (alpha-2c)-antagonisten und einem task1/3-kanalblocker zur behandlung von schlafapnoe
US20220218677A1 (en) 2019-05-09 2022-07-14 Bayer Aktiengesellschaft Arylquinoziline derivatives as alpha2-adrenoceptor subtype c (alpha-2c) antagonists for the treatment of sleep apnea
CN111116578B (zh) * 2019-12-26 2021-06-04 深圳市老年医学研究所 去亚甲基小檗碱的制备方法及其应用
MX2023000369A (es) 2020-07-06 2023-02-13 Bayer Ag Combinación de antagonistas del receptor adrenérgico a2 subtipo c (alfa 2c) con un bloqueador de canales task1/3 para el tratamiento de la apnea del sueño.
CN112457314A (zh) * 2020-11-19 2021-03-09 烟台大学 手性吲哚并吲哚里西啶类化合物及其制备方法
CN116143783B (zh) * 2021-11-23 2024-09-20 中国科学院大连化学物理研究所 一种单萜吲哚生物碱化合物及其制备和应用及药物
WO2023118098A1 (en) 2021-12-22 2023-06-29 Bayer Aktiengesellschaft COMBINATION OF AN α2-ADRENOCEPTOR SUBTYPE C (ALPHA-2C) ANTAGONISTS WITH A MUSCARINIC RECEPTOR ANTAGONIST FOR THE TREATMENT OF SLEEP APNEA
IL313646A (en) 2021-12-22 2024-08-01 Bayer Ag Combination of an α2-adrenoceptor subtype c (alpha-2c) antagonist with a norepinephrine reuptake inhibitor for the treatment of sleep apnea
KR20240132345A (ko) 2022-01-07 2024-09-03 바이엘 악티엔게젤샤프트 수면 무호흡의 치료를 위한 2,3-디히드로벤조[b][1,4]디옥신-2-일메틸)피페라진-1-일 유도체
MX2024008523A (es) 2022-01-07 2024-07-19 Bayer Ag Antagonistas del adrenoceptor a2 subtipo c para el tratamiento de la apnea del sue?o.
WO2025068514A1 (en) 2023-09-28 2025-04-03 Bayer Aktiengesellschaft Substituted heterocyclic carboxamindes and use thereof

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1209650A (fr) 1957-09-12 1960-03-02 Hoffmann La Roche Procédé pour la préparation de dérivés d'indolo-quinolizines
GB844342A (en) 1958-04-24 1960-08-10 Roche Products Ltd Novel quinolizine derivatives and a process for the manufacture thereof
GB983848A (en) 1960-03-12 1965-02-17 Philips Nv Improvements in or relating to indoloquinolizine compounds
FR1524953A (fr) 1962-03-26 1968-05-17 Konink Pharmaceutische Fabrike Procédé de préparation des dérivés de la quinolizine
GB1003645A (en) 1962-10-09 1965-09-08 Koninklijke Pharma Fab Nv Indolo-indolizine compounds
US3203961A (en) * 1963-03-21 1965-08-31 Indolylethylpyrromdone compounds
US3492303A (en) * 1967-07-28 1970-01-27 Warner Lambert Pharmaceutical 1,2,3,4,4a,5,6,8,9,14,14b,14c-dodecahydrobenz(h)indolo(2,3-a)quinolizines
GB1435573A (en) 1973-05-25 1976-05-12 Wyeth John & Brother Ltd Indoloquinolizines
HU170495B (de) * 1974-05-07 1977-06-28
US4044012A (en) * 1974-05-07 1977-08-23 Richter Gedeon Vegyeszeti Gyar Rt. Indolo-quinolizidine derivatives
FR2478639A1 (fr) 1980-03-20 1981-09-25 Sanofi Sa Nouveaux derives de l'indolizino (8,7-b) indole et intermediaires, leur procede de preparation et leur utilisation en therapeutique
GB2106909B (en) 1981-10-07 1984-09-19 Wyeth John & Brother Ltd Benzoquinolizines
EP0089926A3 (de) 1982-03-24 1984-05-16 Ciba-Geigy Ag Pharmazeutische Präparate enthaltend stickstoffhaltige Tetracyclen sowie neue Verbindungen dieser Art
HU188022B (en) * 1983-06-29 1986-03-28 Richter Gedeon Vegyeszeti Gyar Rt,Hu Process for production of derivatives of indolo /2,3-g/cyylopent /a/ indolizin
GB2167408B (en) 1984-11-23 1988-05-25 Farmos Oy Substituted imidazole derivatives and their preparation and use
HU194221B (en) * 1985-04-19 1988-01-28 Richter Gedeon Vegyeszet Process for preparing novel octahydro-indolo/2,3-a/quinoline derivative and pharmaceutical comprising this compound
US4710504A (en) * 1986-04-04 1987-12-01 Merck & Co., Inc. Anti-depressant spiro hexahydro arylquinolizine derivatives, composition, and method of use therefor
NZ216283A (en) 1985-06-03 1989-10-27 Merck & Co Inc Hexahydro arylquinolizine derivatives and pharmaceutical compositions
AU582663B2 (en) * 1985-08-10 1989-04-06 John Wyeth & Brother Limited Sulphonamides
US4686226A (en) * 1985-09-03 1987-08-11 Merck & Co., Inc. Substituted benzo[b]furo- and benzo[b]thieno quinolizines
US5902807A (en) * 1997-05-12 1999-05-11 Antti Haapalinna Method for the treatment of mental illness in mammals and a composition therefor
BR9813381A (pt) 1997-12-04 2000-10-03 Allergan Sales Inc "derivados de imidazol substituìdo possuindo atividade semelhante a agonista em receptores adrenérgicos alfa 2b ou 2b/2c"
FI20000480A0 (fi) 2000-03-01 2000-03-01 Orion Yhtymae Oyj Kinoliini- ja naftaleenijohdannaisia alfa-2 antagonisteina

Also Published As

Publication number Publication date
DE60316672T2 (de) 2008-07-17
US20060094740A1 (en) 2006-05-04
MXPA04009601A (es) 2004-12-13
CA2480695A1 (en) 2003-10-09
RS87204A (sr) 2006-10-27
HK1075660A1 (en) 2005-12-23
US20070293527A9 (en) 2007-12-20
BR0309028A (pt) 2005-02-15
NZ535950A (en) 2007-11-30
EP1490361A1 (de) 2004-12-29
ATE374773T1 (de) 2007-10-15
DE60316672D1 (de) 2007-11-15
AU2003216760A1 (en) 2003-10-13
PL372657A1 (en) 2005-07-25
US7592350B2 (en) 2009-09-22
CN1646528A (zh) 2005-07-27
EA008537B1 (ru) 2007-06-29
HUP0500201A2 (hu) 2005-07-28
EP1490361B1 (de) 2007-10-03
JP2005522468A (ja) 2005-07-28
WO2003082866A1 (en) 2003-10-09
IS7482A (is) 2004-10-01
EA200401301A1 (ru) 2005-06-30
IL164203A0 (en) 2005-12-18
CN100372845C (zh) 2008-03-05

Similar Documents

Publication Publication Date Title
IL164203A0 (en) Polycyclic compounds as potent alpah2-adrenoceptorantagonists
LUC00155I2 (de)
DE69831868D1 (en) Antithrombosemittel
MXPA05012415A (es) Inhibidores de glutamina fructosa-3-fosfato amidotransferasa (gfat).
GEP20064005B (en) Use of novel benzoimidazole derivatives as antiproliferative agents
ATE297203T1 (de) Antithrombotische mitteln
EP1072592A3 (de) 4-Arylpiperidinderivate zur Behandlung von Pruritus
AU2001280438A1 (en) Substituted heterocyclic amides
WO2001064645A3 (en) Derivatives of quinoline as alpha-2 antagonists
TW200608972A (en) Aryl-pyridine derivatives
MXPA05011411A (es) 1,4-diazepinas sustituidas y usos de las mismas.
GEP20094605B (en) Pyrazole derivatives, compositions containing such compounds and methods of use thereof
EA200200510A1 (ru) 4-карбоксиамино-2-этил-1,2,3,4-тетрагидрохинолин в кристаллической форме как ингибитор сетр
WO2004048352A3 (en) 2-cyanopyrrolidines and their analogues as dpp-iv inhibitors
AU2267495A (en) Benzamide derivatives as vasopressin antagonists
GEP20074045B (en) (4-phenyl) piperidin-3-yl-phenylcarboxylate derivatives and related compounds as beta-secretase inhibitors for the treatment of alzheimer's disease
TW200420545A (en) 1-(4-benzyl-piperazin-1-yl)-3-phenyl-propenone derivatives
ATE402175T1 (de) 4-oxo-1-(3-substituiertesphenyl)-1,4-dihydro-1, - naphthyridin-3-carbonsäureamide alsphoshodiesterase-4-inhibitoren
AU2364000A (en) Heterocyclic amides as inhibitors of factor xa
DE60114640D1 (en) Antithrombosemittel
WO1999004770A3 (en) A pharmaceutical composition active in reducing production of mcp-1 protein
MY139228A (en) Imidazolinylmethyl aralkylsulfonamides
CA2089207A1 (en) Amphoteric Tricyclic Compound
CA2309485A1 (en) New 4-arylpiperidine derivatives for the treatment of pruritus
WO2002017954A1 (fr) Medicaments contre la maladie de parkinson

Legal Events

Date Code Title Description
A1OB Publication of a patent application
AIPI Request for the grant of a patent on the basis of a substantive examination of a patent application
ODRP Renewal fee for the maintenance of a patent

Payment date: 20080325

Year of fee payment: 6

ODBC Application rejected